Three strategies for managing loss of exclusivity successfully

“Patent losses could sink Allergan”.

“Drug prices to plummet in wave of expiring patents”.

“Price decay after loss of brand exclusivity”.

These are just three headlines that come up when you Google “drug patent expiry”. It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug manufacturers – shrouded in the threat of job losses and falling share prices.